287194-41-6

Basic information

• Product Name: (+)-DHMEQ
• Synonyms: (1R,2R,6R)-Dehydroxymethylepoxyquinomicin;(1R,2R,6R)-DHMEQ
• CAS NO: 287194-41-6
• Molecular Formula: C13H11NO5
• Molecular Weight: 261.23014
• Mol File: 287194-41-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (+)-DHMEQ(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-DHMEQ(287194-41-6)
• EPA Substance Registry System: (+)-DHMEQ(287194-41-6)

Safety Data

• Hazardous Substances Data: 287194-41-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(+)-DHMEQ is used as a therapeutic agent for its potential anti-inflammatory and anti-tumor properties. It is particularly effective in suppressing the activation of NF-κB, which leads to the inhibition of inflammatory cytokines and the induction of apoptosis in cancer cells.
Used in Treatment of Inflammatory and Autoimmune Diseases:
(+)-DHMEQ is used as a potential treatment for various inflammatory and autoimmune diseases due to its ability to suppress the activation of NF-κB, thereby reducing inflammation and promoting cell survival.
Used in Cancer Therapy:
(+)-DHMEQ is used as a potential candidate for cancer therapy, as it has demonstrated promising results in preclinical studies for the treatment of certain types of cancer. Its ability to induce apoptosis in cancer cells and inhibit inflammatory cytokines makes it a valuable asset in the development of new cancer treatments.

Upstream product

• 287194-41-6 2-hydroxy-N-(2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)benzamide 
• 287194-37-0 N-(2,5-dioxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)-2-hydroxybenzamide 
• 287194-32-5 N-(2,2-dimethoxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)-2-hydroxybenzamide 
• 287194-30-3 acetic acid 2-(2,5-dimethoxyphenylcarbamoyl)phenyl ester 
• 287194-31-4 acetic acid 2-(6,6-dimethoxy-3-oxocyclohexa-1,4-dienylcarbamoyl)phenyl ester 
• 5538-51-2 O-acetylsalicyloyl chloride 
• 1246285-28-8 (2S,3R)-2,3-epoxy-5-[(2-hydroxybenzoyl)amino]cyclohex-5-ene-1,4-dione 
• 1417795-70-0 2-[(2-acetoxybenzoyl)amino]cyclohexa-2,5-diene-1,4-dione 

Relevant articles and documents

A chemo-enzymatic expeditious route to racemic dihexanoyl (2R*,3R*,4R*)-dehydroxymethylepoxyquinomycin (DHMEQ), the precursor for lipase-catalyzed synthesis of the potent nuclear factor-κB inhibitor, (2 S,3S,4 S )-DHMEQ

In order to synthesize the potent nuclear factor (NF)- κB inhibitor, (2S ,3 S ,4 S )-dehydroxymethylepoxyquinomycin (DHMEQ), in a large scale, a new route for its corresponding racemic precursor, dihexanoyl (2R*,3R*, 4R*)- DHMEQ, was developed. By employi

Chemoenzymatic synthesis of (2R,3R,4R)-Dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2

Dehydroxymethylepoxyquinomicin (DHMEQ, 1a) is a specific and potent inhibitor of NF-κB, and it is now being developed as an anti-inflammatory and anticancer agent. While previously only the (2S,3S,4S)-form had been available from the racemate by using lip

Chemoenzymatic synthesis of (2S,3S,4S)-form, the physiologically active stereoisomer of dehydroxymethylepoxyquinomicin (DHMEQ), a potent inhibitor on NF-κB

A new route for (2S,3S,4S)-form, the physiologically active stereoisomer of dehydroxymethylepoxyquinomicin (DHMEQ), a potent NF-κB inhibitor, was established by chemoenzymatic approach. Elaboration on the asymmetric epoxidation of a p-benzoquinone monoket

DHMEQ AS A SENSITIZING AGENT FOR CHEMOTHERAPY AND IMMUNOTHERAPY OF RESISTANT CANCER CELLS

The present invention for the first time identifies DHMEQ as a sensitizing agent for therapy (e.g., chemotherapy, hormonal therapy, radiotherapy and immunotherapy) of resistant and sensitive cells. The present invention therefore provides methods of treat

DRUG COMPOSITION CONTAINING NF-KAPPA B INHIBITOR

Pharmaceutical compositions for improving at least one symptom resulting from tumor cells, which contains a compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof as an active ingredient. wherein R1/

Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor

NF-κB is a transcription factor that induces inflammatory cytokines and anti-apoptotic proteins. We have designed a new NF-κB inhibitor based on the structure of the antibiotic epoxyquinomicin C. The designed compound, dehydroxymethylepoxyquinomicin (DHME

Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C

In order to develop new inhibitors of NF-κB activation, we designed and synthesized dehydroxymethyl derivatives of epoxyquinomicin C, namely, DHM2EQ and its regioisomer DHM3EQ. These derivatives were synthesized from 2,5-dimethoxyaniline in 5 steps. Since DHM2EQ was more active and less toxic than DHM3EQ, its stereochemical configuration was determined by X-ray crystallographic analysis. Each enantiomer of the protected DHM2EQ was separated by a chiral column and deprotected. DHM2EQ inhibited TNF-α-induced activation of NF-κB in human T cell leukemia cells, and also inhibited collagen-induced arthritis in a rheumatoid model in mice. (C) 2000 Elsevier Science Ltd. All rights reserved.